Shanghai Hengrui Pharmaceutical Co., Ltd.;Jiangsu Hengrui Medicine Co., Ltd.
发明人:
申请号：
EP18798641.9
公开号：
EP3623389A1
申请日:
2018.05.11
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention provides a fusion protein containing TGF-β receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-βRII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-β receptor, and the use thereof in the preparation of anti-cancer drug.
